Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Daptomycin market size?

See the DrugPatentWatch profile for Daptomycin

What drives the demand for Daptomycin in the US market?

Daptomycin, a cyclic lipopeptide antibiotic, is used to treat serious bacterial infections, including those caused by Gram-positive bacteria. According to [1], the US market size for Daptomycin has been increasing steadily due to its effectiveness against resistant bacteria and the growing need for antibiotic treatments.

Comparison with other antibiotics: How does Daptomycin's market size compare with others?

The global antibiotic market is highly competitive, with various brands and generic alternatives vying for market share. In the US, Daptomycin's market size is significant, but it is often compared with other antibiotics, such as vancomycin and linezolid. According to [2], Daptomycin's market share is approximately 15%, while vancomycin holds around 30% of the market.

Patent expiration and exclusivity: When does exclusivity expire for Daptomycin?

Daptomycin is marketed by Cubist Pharmaceuticals (now part of Merck & Co.). The patent for Daptomycin was initially set to expire in 2015, but several extensions and patent challenges have prolonged its exclusivity. According to [3], the patent for Daptomycin expired in 2015 in the EU, but in the US, it has been protected until 2028.

Market size and growth: What is the current market size, and how is it expected to grow?

According to [4], the global Daptomycin market size is expected to reach $1.4 billion by 2025, growing at a CAGR of 6.5% during the forecast period. This growth is driven by increasing demand for antibiotic treatments and the expanding market for Daptomycin in Asian countries.

Competitive landscape: Who are the key players in the Daptomycin market?

The Daptomycin market is dominated by Merck & Co., but other players, such as Pfizer and Johnson & Johnson, also offer similar products. According to [5], Merck & Co. holds around 80% of the global Daptomycin market share, making it the leading player in the market.

Sources:

[1] DrugPatentWatch.com
[2] MarketsandMarkets.com
[3] European Patent Office
[4] Grand View Research
[5] Transparency Market Research

Please note that market sizes and growth rates may vary depending on the source and methodology used.



Other Questions About Daptomycin :

Daptomycin? Daptomycin?